Partners seek EUA for COVID-19 booster jab in kids aged five to 11

27 April 2022
biontech_vaccine_large

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10µg booster dose of their COVID-19 jab for children aged five to 11 years of age.

The submission included data from the Phase II/III trial in children aged five through 11 years who received a booster dose approximately six months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10µg two-dose primary series, which was authorized under EUA for this age group in October 2021.

Data from the study demonstrated a strong immune response in this age group following a booster dose of the vaccine. There were no new safety signals reported.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology